It has already been recognized for some years that certain molecules of plant origin act in the body in a way similar to estrogens naturally produced by the body. Since then, views have been divided on the effects of these estrogenically active plants on reducing menopausal symptoms, lowering cholesterol levels, and preventing osteoporosis and cancer.
Most recently, a European study conducted by a team of Italian researchers attempted to demonstrate that a number of chemical compounds derived from plants, known as phytoestrogens, have the ability to bind to estrogen receptors, producing estrogenic or anti-estrogenic activity. The team of professionals identified structurally related homoisoflavones isolated from a perennial bulbous plant called Leopoldia comosa, potentially useful as hormonal substitutes or supplements in the treatment of breast cancer. The potential antiproliferative effects of these compounds could indeed be used in the formulation of nutraceuticals or pharmaceuticals. Therefore, this study can be considered as the starting point for the identification of new tools for the treatment of estrogen-sensitive cancer. For more information…
This Year at BÉNÉFIQ 2018
Well known for her commitment in promoting women’s health, Sylvie Dodin-Dewailly, clinical researcher at the Institute of Nutrition and Functional Foods (INAF), will present her latest work during session 2 “Nutrition et Santé des femmes” of BÉNÉFIQ 2018. This gynecologist and full professor in the Department of Obstetrics and Gynaecology at Hôpital Saint-François d’Assise at the CHU de Québec will focus on the impact of phytoestrogens on breast cancer.